3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
3
Sarcoma
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Hodgkin Disease
47
Lymphoma
22
Lymphoma, Non-Hodgkin
18
Lymphoma, Large B-Cell, Diffuse
15
Multiple Myeloma
12
Melanoma
9
Lymphoma, B-Cell
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Hematologic Neoplasms
9
Lymphoma, Follicular
7
Myelodysplastic Syndromes
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Lymphoma, Large-Cell, Anaplastic
5
Carcinoma, Renal Cell
5
Burkitt Lymphoma
5
Uterine Cervical Neoplasms
4
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm Metastasis
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, B-Cell, Marginal Zone
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Breast Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Pancreatic Neoplasms
3
Interventions
Cyclophosphamide
260
fludarabine phosphate
163
Methotrexate
124
Rituximab
112
Cytarabine
109
Filgrastim
106
fludarabine
92
Busulfan
86
Peripheral Blood Stem Cell Transplantation
83
Etoposide
82
Vincristine
80
Radiotherapy
79
Tacrolimus
73
Mycophenolic Acid
72
Antilymphocyte Serum
68
Whole-Body Irradiation
66
Melphalan
63
Dexamethasone
63
Cyclosporine
58
Doxorubicin
51
Prednisone
44
Methylprednisolone
44
Alemtuzumab
44
Mercaptopurine
41
Granulocyte Colony-Stimulating Factor
40
pegaspargase
35
Daunorubicin
34
Clofarabine
33
Thiotepa
31
Asparaginase
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Nivolumab
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts